$0.8888
0.0183[2.10%]
At close: Apr 24
$0.8888
0[0.00%]
PreMarket: 6:02AM EDT
Ginkgo Bioworks Holdings
(NYSE:DNA)Ginkgo Bioworks Holdings Stock (NYSE:DNA), Analyst Ratings, Price Targets, Predictions
Ginkgo Bioworks Holdings Inc has a consensus price target of $5.45, established from looking at the 23 latest analyst ratings. The last 3 analyst ratings were released from TD Cowen, Goldman Sachs, and Goldman Sachs on March 1, 2024, January 23, 2024, and January 22, 2024. With an average price target of $1.73 between TD Cowen, Goldman Sachs, and Goldman Sachs, there's an implied 95.02% upside for Ginkgo Bioworks Holdings Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
TD Cowen
Goldman Sachs
Raymond James
BTIG
William Blair
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Ginkgo Bioworks Holdings
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/01/2024 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | 237.53% | TD Cowen | Steven Mah | $7 → $3 | Maintains | Outperform | Get Alert |
| 01/23/2024 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | 23.76% | Goldman Sachs | Matthew Sykes | $1.25 → $1.1 | Maintains | Sell | Get Alert |
| 01/22/2024 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | 23.76% | Goldman Sachs | Matthew Sykes | $1.25 → $1.1 | Maintains | Sell | Get Alert |
| 11/15/2023 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | 181.28% | Raymond James | Rahul Sarugaser | → $2.5 | Downgrade | Outperform → Market Perform | Get Alert |
| 11/14/2023 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | 181.28% | Raymond James | Rahul Sarugaser | → $2.5 | Downgrade | Outperform → Market Perform | Get Alert |
| 11/09/2023 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | — | BTIG | Mark Massaro | — | Downgrade | Buy → Neutral | Get Alert |
| 06/05/2023 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | 40.64% | Goldman Sachs | Matthew Sykes | $3 → $1.25 | Maintains | Sell | Get Alert |
| 06/02/2023 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | 40.64% | Goldman Sachs | Matthew Sykes | $3 → $1.25 | Downgrade | Neutral → Sell | Get Alert |
| 05/11/2023 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | — | William Blair | Matt Larew | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/29/2022 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | 575.07% | Berenberg | Gaurav Goparaju | → $6 | Initiates | → Buy | Get Alert |
| 10/04/2022 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | 462.56% | Morgan Stanley | Tejas Savant | → $5 | Initiates | → Equal-Weight | Get Alert |
| 08/16/2022 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | 575.07% | BTIG | Mark Massaro | $5 → $6 | Maintains | Buy | Get Alert |
| 08/16/2022 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | 1531.41% | Raymond James | Rahul Sarugaser | $11.5 → $14.5 | Maintains | Outperform | Get Alert |
| 06/16/2022 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | 389.42% | Jefferies | Laurence Alexander | $11.5 → $4.35 | Maintains | Buy | Get Alert |
| 05/18/2022 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | 237.53% | B of A Securities | Derik De Bruin | $6 → $3 | Downgrade | Neutral → Underperform | Get Alert |
| 03/02/2022 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | 1250.14% | Cowen & Co. | Steven Mah | → $12 | Initiates | → Outperform | Get Alert |
| 02/23/2022 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | 687.58% | Goldman Sachs | Matthew Sykes | → $7 | Initiates | → Neutral | Get Alert |
| 02/01/2022 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | 575.07% | B of A Securities | Derik De Bruin | → $6 | Initiates | → Neutral | Get Alert |
| 01/28/2022 | DNA | Buy Now | Ginkgo Bioworks Holdings | $0.89 | 800.09% | B of A Securities | Derik De Bruin | → $8 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Ginkgo Bioworks Holdings (DNA)?
The latest price target for Ginkgo Bioworks Holdings (NYSE: DNA) was reported by TD Cowen on March 1, 2024. The analyst firm set a price target for $3.00 expecting DNA to rise to within 12 months (a possible 237.53% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ginkgo Bioworks Holdings (DNA)?
The latest analyst rating for Ginkgo Bioworks Holdings (NYSE: DNA) was provided by TD Cowen, and Ginkgo Bioworks Holdings maintained their outperform rating.
When was the last upgrade for Ginkgo Bioworks Holdings (DNA)?
There is no last upgrade for Ginkgo Bioworks Holdings.
When was the last downgrade for Ginkgo Bioworks Holdings (DNA)?
The last downgrade for Ginkgo Bioworks Holdings Inc happened on November 15, 2023 when Raymond James changed their price target from N/A to $2.5 for Ginkgo Bioworks Holdings Inc.
When is the next analyst rating going to be posted or updated for Ginkgo Bioworks Holdings (DNA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ginkgo Bioworks Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ginkgo Bioworks Holdings was filed on March 1, 2024 so you should expect the next rating to be made available sometime around March 1, 2025.
Is the Analyst Rating Ginkgo Bioworks Holdings (DNA) correct?
While ratings are subjective and will change, the latest Ginkgo Bioworks Holdings (DNA) rating was a maintained with a price target of $7.00 to $3.00. The current price Ginkgo Bioworks Holdings (DNA) is trading at is $0.89, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.